Although further studies are needed to evaluate the antitumor efficiency of CCL2/CCR2 axis blockade in GBM patients, it is worth noting that CCL2 neutralizing antibody (e.g., carlumab) shows a modest effect in patients with prostate cancer (68). Here, CCL2 is linked to glioblastoma.